FDA EIR - Patheon Austria GmbH & Co. KG - January 31, 2020

An FDA Pre-Approval Inspection was conducted at Patheon Austria GmbH & Co. KG in Linz, Austria, from January 27 to January 31, 2020. This inspection focused on the firm's role as a contract manufacturer for a specific drug substance (Active Pharmaceutical Ingredient or API) intended for the U.S. market. The inspection, guided by FDA compliance programs (CPGM 7346.832, CPGM 7356.002F) and ICH Q7 Good Manufacturing Practice guidance for APIs, covered key systems including Quality, Production, Facilities & Equipment, Materials, and Laboratory Control. Its objective was to assess the facility's readiness for commercial manufacturing and conformance to the application. Significantly, at the conclusion of this five-day inspection, no FDA-483 Inspectional Observations were issued to Patheon Austria GmbH & Co. KG. This indicates that the facility was found to be operating in a state of compliance with current Good Manufacturing Practices during this assessment. While the report detailed internal deviations and process improvements made by the company, these were managed internally and did not result in regulatory observations from the FDA during this inspection. Consequently, no immediate regulatory actions were required from the firm based on this specific FDA inspection.